COMBINATION OF PLATELET FIBRINOGEN RECEPTOR ANTAGONIST AND DIRECT THROMBIN INHIBITOR AT LOW-DOSES MARKEDLY IMPROVES THROMBOLYSIS

被引:82
作者
NICOLINI, FA [1 ]
LEE, P [1 ]
RIOS, G [1 ]
KOTTKEMARCHANT, K [1 ]
TOPOL, EJ [1 ]
机构
[1] CLEVELAND CLIN FDN, HEMOSTASIS THROMBOSIS LAB, CLEVELAND, OH USA
关键词
PLASMINOGEN ACTIVATORS; INTEGRELIN; HIRUDIN; THROMBOSIS;
D O I
10.1161/01.CIR.89.4.1802
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We evaluated the effects of a novel platelet fibrinogen receptor antagonist, Integrelin, and a direct thrombin inhibitor, recombinant hirudin, given together with recombinant tissue plasminogen activator (rTPA) in a canine experimental model of intracoronary thrombosis. We tested the hypothesis that combination of both agents at low doses would have an additive antithrombotic effect, resulting in a significant improvement in the efficacy of rTPA. Methods and Results Thirty-two dogs with an electrically induced coronary thrombus were treated with rTPA (1 mg/kg over 20 minutes) together with one of the following adjunctive treatments in a random fashion. Eight dogs received saline for 90 minutes; Integrelin (5 mu g.kg(-1).min(-1) for 90 minutes) was given to 8 dogs; 8 dogs received recombinant hirudin (20 mu g.kg(-1).min(-1) for 90 minutes); and 8 dogs were treated with a low-dose combination of Integrelin (2.5 mu g.kg(-1).min(-1)) plus recombinant hirudin (10 mu g.kg(-1).min(-1)) for 90 minutes. Integrelin or recombinant hirudin, when given as single adjunct to rTPA, enhanced the lysis of the occlusive thrombus, causing full restoration of coronary blood flow (100% of its baseline value) for 29+/-16 and 26+/-5 minutes, respectively, whereas coronary blood flow was fully restored for only 5+/-1 minutes in dogs receiving rTPA plus saline (both P<.05). However, either Integrelin or recombinant hirudin failed to modify the reocclusion rate (57% and 63%, respectively) compared with saline (83%; all P=NS). Conversely, the low-dose combination therapy led to complete restoration of coronary blood flow for 92+/-19 minutes (P<.01 versus all treatments) and significantly reduced the reocclusion rate (25%; P<.05 versus saline). Conclusions These data show that inhibition of specific pathways of platelet and thrombin activity improves the extent and duration of rTPA-induced thrombolysis in the electrolytic canine model. Furthermore, our findings suggest that low doses of platelet IIb/IIIa and direct thrombin antagonists in combination may be used successfully during thrombolysis.
引用
收藏
页码:1802 / 1809
页数:8
相关论文
共 34 条
  • [1] [Anonymous], 1988, LANCET, V2, P349
  • [2] ADJUVANT ANTIPLATELET STRATEGIES IN CORONARY THROMBOLYSIS
    BECKER, RC
    GORE, JM
    [J]. CIRCULATION, 1991, 83 (03) : 1115 - 1117
  • [3] RELEASE OF THROMBIN FROM FIBRIN BY FIBRINOLYSIN
    BLOOM, AL
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1962, 8 (02) : 129 - &
  • [4] ENHANCEMENT OF THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY PRETREATMENT WITH HEPARIN
    CERCEK, B
    LEW, AS
    HOD, H
    YANO, J
    REDDY, NKN
    GANZ, W
    [J]. CIRCULATION, 1986, 74 (03) : 583 - 587
  • [5] CHARO IF, 1992, CIRCULATION, V86, P260
  • [6] PLATELETS AND THROMBOLYTIC THERAPY
    COLLER, BS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) : 33 - 42
  • [7] DEBONO DP, 1992, BRIT HEART J, V67, P122
  • [8] IMPORTANCE OF CONTINUED ACTIVATION OF THROMBIN REFLECTED BY FIBRINOPEPTIDE-A TO THE EFFICACY OF THROMBOLYSIS
    EISENBERG, PR
    SHERMAN, L
    RICH, M
    SCHWARTZ, D
    SCHECHTMAN, K
    GELTMAN, EM
    SOBEL, BE
    JAFFE, AS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (06) : 1255 - 1262
  • [9] RAPID AND SUSTAINED CORONARY-ARTERY RECANALIZATION WITH COMBINED BOLUS INJECTION OF RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND MONOCLONAL ANTIPLATELET GPIIB/IIIA ANTIBODY IN A CANINE PREPARATION
    GOLD, HK
    COLLER, BS
    YASUDA, T
    SAITO, T
    FALLON, JT
    GUERRERO, JL
    LEINBACH, RC
    ZISKIND, AA
    COLLEN, D
    [J]. CIRCULATION, 1988, 77 (03) : 670 - 677
  • [10] SIMULTANEOUS ADMINISTRATION OF THROMBOXANE-A2-RECEPTOR AND SEROTONIN-S2-RECEPTOR ANTAGONISTS MARKEDLY ENHANCES THROMBOLYSIS AND PREVENTS OR DELAYS REOCCLUSION AFTER TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN A CANINE MODEL OF CORONARY-THROMBOSIS
    GOLINO, P
    ASHTON, JH
    MCNATT, J
    GLASGREENWALT, P
    SHENGKUN, Y
    OBRIEN, RA
    BUJA, LM
    WILLERSON, JT
    [J]. CIRCULATION, 1989, 79 (04) : 911 - 919